Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Last verified 24 Sep 2026 · Editorial standards

Azacitidine is named as a drug or biological intervention in 70 clinical trials in our China, USA, UK and India trial registers, 39 of which are recruiting. Lead sponsors include AbbVie (6), Institute of Hematology & Blood Diseases Hospital, China (5) and The First Affiliated Hospital of Soochow University (4). Registered phases: Phase 2, Phase 1/2, Phase 3, Phase 1, Phase 2/3, Phase 4, Not applicable, Phase EARLY_PHASE1 and Observational. Conditions studied include Acute Myeloid Leukemia; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes.

Clinical trials of Azacitidine

70 trials

NCT ID	Study	Phase	Status	Lead sponsor	Register
NCT07598578	An Open-label, Single-arm, Multicenter Phase II Clinical Study of Azacitidine, Chidamide Combined With PD-1 Monoclonal Antibody in the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma. (ClinicalTrials.gov ↗) Peripheral T-Cell Lymphoma Refractory	Phase EARLY_PHASE1	Recruiting	Second Affiliated Hospital of Soochow University	China
NCT07044687	Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India (ClinicalTrials.gov ↗) Acute Myeloid Leukemia	Phase 4	Recruiting	AbbVie	India
NCT05586074	HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML (ClinicalTrials.gov ↗) Leukemia, Acute Myeloid (AML)	Phase 3	Recruiting	Sunshine Lake Pharma Co., Ltd.	China
NCT06641414	Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4). (ClinicalTrials.gov ↗) Higher-risk Myelodysplastic Syndrome	Phase 3	Recruiting	Ascentage Pharma Group Inc.	USA, China
NCT06647862	IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2) (ClinicalTrials.gov ↗) Chronic Myelomonocytic Leukemia	Phase 3	Recruiting	ImmuneOnco Biopharmaceuticals (Shanghai) Inc.	China
NCT06852222	A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) (ClinicalTrials.gov ↗) Leukemia, Myeloid, Acute	Phase 3	Recruiting	Janssen Research & Development, LLC	UK, USA, China
NCT07007312	Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML (ClinicalTrials.gov ↗) Acute Myeloid Leukemia (AML)	Phase 3	Recruiting	Kura Oncology, Inc.	UK, USA
NCT07132684	Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients (ClinicalTrials.gov ↗) AML, Adult	Phase 3	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
NCT04256317	A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) (ClinicalTrials.gov ↗) Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm	Phase 2/3	Recruiting	Taiho Oncology, Inc.	UK, USA
NCT05404906	AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission (ClinicalTrials.gov ↗) Acute Myeloid Leukemia (AML) in Remission	Phase 2/3	Recruiting	The First Affiliated Hospital of Soochow University	China
NCT07255872	A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia (ClinicalTrials.gov ↗) Acute Myeloid Leukemia	Phase 2/3	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd.	China
NCT07581002	A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) (ClinicalTrials.gov ↗) Acute Myeloid Leukemia	Phase 2/3	Recruiting	AbbVie	USA, China
NCT05736965	A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia (ClinicalTrials.gov ↗) AML, Adult	Phase 2	Recruiting	Shanghai Tong Ren Hospital	China
NCT05736978	Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results (ClinicalTrials.gov ↗) AML, MRD	Phase 2	Recruiting	Shanghai Tong Ren Hospital	China
NCT05958719	Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma Peripheral T Cell Lymphoma, Epigenetic Repression	Phase 2	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
NCT06190067	Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma (ClinicalTrials.gov ↗) Relapsed Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma	Phase 2	Recruiting	Navy General Hospital, Beijing	China
NCT06196203	A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes (ClinicalTrials.gov ↗) Higher-risk Myelodysplastic Syndromes	Phase 2	Recruiting	Akeso	USA, China
NCT06451861	Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML (ClinicalTrials.gov ↗) Acute Myeloid Leukemia	Phase 2	Recruiting	Guangdong Provincial People's Hospital	China
NCT06635681	Efficacy of Venetoclax Combined With Intensive Chemotherapy in Different Subgroups of AML (ClinicalTrials.gov ↗) AML (Acute Myelogenous Leukemia)	Phase 2	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
NCT07047183	Clinical Study of Venetoclax Combined With Azacitidine as Bridging Therapy Prior to Hematopoietic Stem Cell Transplantation in Patients With Higher-Risk Myelodysplastic Syndromes (ClinicalTrials.gov ↗) Myelodysplastic Neoplasms, Transplantation	Phase 2	Recruiting	Yehui Tan	China
NCT07548710	Study of SA+X in the Treatment of Newly Diagnosed AML (ClinicalTrials.gov ↗) Acute Myeloid Leukemia	Phase 2	Recruiting	Ruijin Hospital	China
NCT07743112	A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia (ClinicalTrials.gov ↗) Acute Myeloid Leukemia	Phase 2	Recruiting	Maxinovel Pty., Ltd.	China
NCT03850574	Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia (ClinicalTrials.gov ↗) Leukemia, Myeloid, Acute, Refractory AML, Relapsed Adult AML	Phase 1/2	Recruiting	Aptose Biosciences Inc.	USA
NCT04068597	Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma	Phase 1/2	Recruiting	CellCentric Ltd.	UK, USA
NCT04501120	Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML (ClinicalTrials.gov ↗) Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy	Phase 1/2	Recruiting	Ascentage Pharma Group Inc.	China
NCT04581512	Study to Evaluate the Safety and Tolerability of EP0042 (ClinicalTrials.gov ↗) Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes	Phase 1/2	Recruiting	Ellipses Pharma	UK
NCT04588922	Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML (ClinicalTrials.gov ↗) Hematologic Malignancies	Phase 1/2	Recruiting	Sellas Life Sciences Group	USA, China
NCT04771130	A Study of BGB-11417 in Participants With Myeloid Malignancies Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm	Phase 1/2	Recruiting	BeOne Medicines	UK, USA, China
NCT04988555	A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) (ClinicalTrials.gov ↗) Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, Multiple Myeloma	Phase 1/2	Recruiting	Sumitomo Pharma America, Inc.	UK, USA
NCT05270200	Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse (ClinicalTrials.gov ↗) Leukemia, Myeloid, Acute	Phase 1/2	Recruiting	Zhujiang Hospital	China
NCT07011186	A Clinical Trial of TQB3909 Tablets in Combination With Azacitidine for the Treatment of Myeloid Malignancies (ClinicalTrials.gov ↗) Myeloid Malignancy	Phase 1/2	Recruiting	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	China
NCT04243785	A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (ClinicalTrials.gov ↗) Acute Myeloid Leukemia, Myelodysplastic Syndrome	Phase 1	Recruiting	Edgewood Oncology Inc.	USA
NCT05735184	A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML (ClinicalTrials.gov ↗) Acute Myeloid Leukemia, Mixed Lineage Leukemia Gene Mutation, Refractory AML	Phase 1	Recruiting	Kura Oncology, Inc.	USA
NCT06419634	Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome (ClinicalTrials.gov ↗) Acute Myeloid Leukemia, Myelodysplastic Syndrome	Phase 1	Recruiting	Bristol-Myers Squibb	USA
NCT06634394	APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML Acute Myeloid Leukemia (AML)	Phase 1	Recruiting	Aptevo Therapeutics	USA
NCT06656494	ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies (ClinicalTrials.gov ↗) Acute Myelogenous Leukemia, Myelodysplastic Syndromes (MDS)	Phase 1	Recruiting	Beijing InnoCare Pharma Tech Co., Ltd.	USA, China
NCT06390306	The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP (ClinicalTrials.gov ↗) Chronic Myeloid Leukemia	Observational	Recruiting	Peking University People's Hospital	China
NCT06386302	Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia (ClinicalTrials.gov ↗) AML, Acute Myeloid Leukemia	Not applicable	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
NCT07131059	MRD-positive AML Clinical Study (ClinicalTrials.gov ↗) AML, Adult	Not applicable	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
NCT07486479	Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML (ClinicalTrials.gov ↗) Acute Myeloid Leukemia (AML)	Phase 3	Not yet open	The First Affiliated Hospital of Soochow University	China
NCT07573670	A Phase 2 Study of Bcl-2 Inhibitor Combined With Azacitidine for Newly Diagnosed Mixed Phenotype Acute Leukemia (ClinicalTrials.gov ↗) Newly Diagnosed Mixed Phenotype Acute Leukemia	Phase 2	Not yet open	The First Affiliated Hospital of Soochow University	China
NCT07664839	Study on the Efficacy and Safety of VA Regimen Compared to "3+7" Regimen in Newly Diagnosed AML With NPM1 or IDH1/IDH2 Mutations (ClinicalTrials.gov ↗) Acute Myeloid Leukemia, NPM1 Mutation, IDH1 Mutation	Phase 2	Not yet open	Shen yang	China
NCT07746245	The Efficacy of CAPCT in Patients With PTCL (ClinicalTrials.gov ↗) Peripheral T-Cell Lymphoma	Phase 2	Not yet open	The First Affiliated Hospital with Nanjing Medical University	China
NCT07706959	New Genotype-guided Treatment in Newly Diagnosed PTCL (ClinicalTrials.gov ↗) Peripheral T-cell Lymphoma (PTCL)	Phase 1/2	Not yet open	Ruijin Hospital	China
NCT07722767	A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients (ClinicalTrials.gov ↗) AML (Acute Myeloid Leukemia)	Phase 1	Not yet open	Cullinan Therapeutics Inc.	USA
NCT06841952	Study of Tretinoin Capsules in Combination With Azacitidine and Venetoclax in Treatment Naïve Participants With Acute Myeloid Leukemia (ClinicalTrials.gov ↗) AML, Adult	Not applicable	Not yet open	The First Affiliated Hospital of Soochow University	China
NCT05678933	AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFH (ClinicalTrials.gov ↗) Peripheral T-cell Lymphoma Targeted Therapy	Phase 3	By invitation	Tianjin Medical University Cancer Institute and Hospital	China
NCT07651176	Comparing the Efficacy of the LDA, LHAA, and DA Regimens in Young Adults With Low-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy (ClinicalTrials.gov ↗) Acute Myeloid Leukemia, Lisaftoclax	Phase 2/3	By invitation	First Affiliated Hospital of Zhejiang University	China
NCT07813390	Homoharringtonine, Lisaftoclax, and Azacitidine for AML After Venetoclax-Based Therapy Failure (ClinicalTrials.gov ↗) Acute Myeloid Leukemia (AML)	Phase 2	By invitation	Guangdong Second Provincial General Hospital	China
NCT05144243	Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in China (ClinicalTrials.gov ↗) Acute Myeloid Leukemia (AML)	Phase 4	Active, closed	AbbVie	China
NCT07046182	Clinical Study of CEP+Dasatinib + Azacytidine in First-line Treatment of. Angioimmunoblastoma Foresight (ClinicalTrials.gov ↗) Angioimmunoblastic T-cell Lymphoma (AITL)	Phase 4	Active, closed	Zhengzhou University	China
NCT02993523	A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy (ClinicalTrials.gov ↗) Acute Myeloid Leukemia (AML)	Phase 3	Active, closed	AbbVie	USA, China
NCT03173248	Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation (ClinicalTrials.gov ↗) Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS)	Phase 3	Active, closed	Institut de Recherches Internationales Servier	China
NCT04229979	Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2 (ClinicalTrials.gov ↗) Acute Myeloid Leukemia	Phase 3	Active, closed	Sellas Life Sciences Group	USA, India
NCT04401748	Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome Myelodysplastic Syndrome (MDS)	Phase 3	Active, closed	AbbVie	UK, USA, China
NCT05469737	A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS) (ClinicalTrials.gov ↗) Myelodysplastic Syndromes	Phase 2/3	Active, closed	Bristol-Myers Squibb	USA, China
NCT05197426	A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission (ClinicalTrials.gov ↗) Acute Myeloid Leukemia	Phase 2	Active, closed	Bristol-Myers Squibb	USA
NCT05201066	Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab. (ClinicalTrials.gov ↗) Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic	Phase 2	Active, closed	Novartis Pharmaceuticals	USA, China
NCT06384261	A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy Leukemia, Myeloid, Acute	Phase 2	Active, closed	OncoVerity, Inc.	USA
NCT06456463	A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy Acute Myeloid Leukemia	Phase 2	Active, closed	Stemline Therapeutics, Inc.	USA
NCT02677922	A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy (ClinicalTrials.gov ↗) Leukemia, Myeloid, Acute	Phase 1/2	Active, closed	Celgene	UK, USA
NCT04086264	IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia (ClinicalTrials.gov ↗) Acute Myeloid Leukemia	Phase 1/2	Active, closed	AbbVie	UK, USA
NCT04730258	A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML (ClinicalTrials.gov ↗) Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia	Phase 1/2	Active, closed	Treadwell Therapeutics, Inc	USA
NCT04900350	A Trial of AK117 (Anti-CD47) in Patients With Myelodysplastic Syndrome (ClinicalTrials.gov ↗) Myelodysplastic Syndrome	Phase 1/2	Active, closed	Akeso	China
NCT05428969	A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies (ClinicalTrials.gov ↗) Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes	Phase 1/2	Active, closed	Faron Pharmaceuticals Ltd	UK, USA
NCT05520567	A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia Acute Myeloid Leukemia (AML), FLT3-mutated Acute Myeloid Leukemia	Phase 1/2	Active, closed	Astellas Pharma Global Development, Inc.	USA
NCT04150887	Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia (ClinicalTrials.gov ↗) Leukemia, Myeloid, Acute	Phase 1	Active, closed	OncoVerity, Inc.	USA
NCT04227847	A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies (ClinicalTrials.gov ↗) Myelodysplastic Syndrome, Acute Myeloid Leukemia	Phase 1	Active, closed	Seagen, a wholly owned subsidiary of Pfizer	USA
NCT04603001	Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations (ClinicalTrials.gov ↗) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML)	Phase 1	Active, closed	Eli Lilly and Company	USA, China
NCT05453903	A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies Leukemia, Myeloid, Acute	Phase 1	Active, closed	Janssen Research & Development, LLC	UK, USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Conditions studied

57 conditions

Condition (as registered)	Trials
Acute Myeloid Leukemia	23
Leukemia, Myeloid, Acute	9
Myelodysplastic Syndromes	8
Acute Myeloid Leukemia (AML)	8
Chronic Myelomonocytic Leukemia	5
Myelodysplastic Syndrome	4
AML, Adult	4
AML	3
Multiple Myeloma	2
Myelodysplastic Syndrome (MDS)	2
Refractory AML	2
Myeloid Malignancy	2
Haematological Malignancy	1
Non Hodgkin Lymphoma	1
Myelodysplastic/Myeloproliferative Neoplasm	1
Relapsed/Refractory AML	1
Leukemia, Lymphocytic, Acute	1
Myelodysplastic Syndrome/Neoplasm	1
FLT3-mutated Acute Myeloid Leukemia	1
Higher-risk Myelodysplastic Syndrome	1
Leukemia, Myelomonocytic, Chronic	1
Hematologic Malignancies	1
Mixed Lineage Leukemia Gene Mutation	1
AML With Mutated NPM1	1
Acute Myelogenous Leukemia	1
Myelodysplastic Syndromes (MDS)	1
AML (Acute Myeloid Leukemia)	1
Higher-risk Myelodysplastic Syndromes	1
Chronic Myelomonocytic Leukemia (CMML)	1
Myeloproliferative Neoplasms (MPNs)	1
Relapsed Adult AML	1
Myelodysplastic Syndrome With Excess Blasts-2	1
Peripheral T Cell Lymphoma	1
Epigenetic Repression	1
Relapsed/Refractory Acute Myeloid Leukaemia	1
Newly Diagnosed Mixed Phenotype Acute Leukemia	1
NPM1 Mutation	1
IDH1 Mutation	1
IDH2 Mutation	1
Peripheral T-cell Lymphoma Targeted Therapy	1

+ 17 more conditions in the trial records above.

Trials by country register

Register	Azacitidine trials
Clinical trials in China	46
Clinical trials in USA	34
Clinical trials in UK	12
Clinical trials in India	2

A trial with sites in more than one country appears in each of those registers.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Azacitidine works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Azacitidine (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Azacitidine

Clinical trials of Azacitidine

Conditions studied

Sponsors

Trials by country register

How this page is built